CBLB
CBLBgeneCBLB regulates acute myocardial infarction through immune cell activation and metabolic responses affecting plaque inflammation and systemic metabolic stress.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleRegulates immune and metabolic pathways in AMI.
Also acts inLipid entry/oxidation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000114423
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I20
C — confounder / Type-II41
A — assay feasibility52
E — evidence strength16
T1DI (composite)3
Specificity differential (R−C)-20.9
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable
Literature evidence(1)
- Exploring the role of CBLB in acute myocardial infarction: transcriptomic, microbiomic, and metabolomic analyses.Journal of translational medicine · 2024 · PMID 39004726 · doi